| 3530 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
en |
Isabel’s Story: How she and her family learned about osteoporosis and bone health. |
This is a story about Isabel and how she and her family learned about osteoporosis and bone health. |
| NIH Osteoporosis | 0.397359 |
| metabolic bone diseases | 0.379463 |
| better bone health | 0.382713 |
| NIH Publication No. | 0.365411 |
| door frame | 0.386277 |
| mom | 0.350341 |
| family tradition | 0.342446 |
| middle-aged woman | 0.341978 |
| later… isabel | 0.576126 |
| great grandmother | 0.367598 |
| newborn baby | 0.358422 |
| family members | 0.342417 |
| refrigerator door | 0.342927 |
| Osteoporosis risk factors | 0.383474 |
| bone health | 0.530027 |
| osteoporosis | 0.437189 |
| friends | 0.348537 |
| phone | 0.342772 |
| husband Juan | 0.422731 |
| bones | 0.346886 |
| Related Bone Diseases | 0.458258 |
| dog | 0.34131 |
| test measures bone | 0.381985 |
| Isabel | 0.938161 |
| Isabel’s feet | 0.509084 |
|
| Juan whispers | 0.352343 |
| Doña Carla | 0.74756 |
| Beep | 0.347782 |
| grandson Néstor | 0.376707 |
| Isabel answers | 0.508932 |
| daughter Elena | 0.418745 |
| Happy Birthday | 0.36175 |
| bone density test | 0.466172 |
| kitchen | 0.439823 |
| new camera | 0.367655 |
| mother Doña Carla | 0.402266 |
| National Resource Center | 0.452613 |
| warning signs | 0.359764 |
| Doña Isabel | 0.549661 |
| kitchen door | 0.349718 |
| son Tony | 0.412089 |
| doctor | 0.416292 |
| brother Tony | 0.343301 |
| birthday cake | 0.36894 |
| Tony’s friend | 0.342202 |
| Ring | 0.350598 |
| Isabel’s mother | 0.50536 |
| Juan | 0.45419 |
| family | 0.430288 |
|
CLICK HERE |
| 3545 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
es |
¿Qué es el acné? (Esenciales: hojas informativas de fácil lectura) |
El acné es una enfermedad que afecta las glándulas sebáceas. El acné es la enfermedad de la piel más común. Las personas de todas las razas y de todas las edades pueden tener acné. |
| Health Statistics | 0.387369 |
| glándulas sebáceas | 0.945868 |
| datos abiertos lista | 0.460697 |
| Disease Control | 0.377137 |
| Centro Nacional | 0.361634 |
| adultos jóvenes | 0.820766 |
|
| sustancia grasosa llamada | 0.704803 |
| privacidad acceso | 0.351992 |
| NIAMS FOIA Aviso | 0.545075 |
| pequeños orificios | 0.468319 |
| vÃa oral | 0.424285 |
|
CLICK HERE |
| 3546 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
Html |
es |
¿Qué es la fibromialgia? (Esenciales: hojas informativas de fácil lectura) |
La fibromialgia es un trastorno que causa dolores musculares y fatiga (cansancio). Las personas con fibromialgia tienen “puntos hipersensibles” en el cuerpo. Las personas que padecen de fibromialgia pueden también tener otros síntomas. |
| datos abiertos lista | 0.684212 |
| Mala memoria | 0.712723 |
| Centro Nacional | 0.614702 |
| principales sÃntomas | 0.701501 |
| NIAMS FOIA Aviso | 0.730336 |
| actividades relajantes | 0.635234 |
| Enter email address | 0.717473 |
|
| larga duración | 0.958254 |
| sueño reparador | 0.714685 |
| fuerte reacción | 0.713228 |
| siguientes acontecimientos | 0.706276 |
| siguientes medicamentos | 0.695912 |
| privacidad acceso | 0.606511 |
|
CLICK HERE |
| 15537 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Flu (Influenza) Vaccine Research |
NIAID flu vaccine research |
| risk assessment | 0.247548 |
| influenza infection | 0.280409 |
| 2014-2015 flu season | 0.47415 |
| flu vaccine production | 0.613927 |
| newly emerging influenza | 0.34218 |
| research efforts | 0.247925 |
| seasonal flu vaccines | 0.542694 |
| annual seasonal flu | 0.471143 |
| Disease Control | 0.250505 |
| new flu strain | 0.471191 |
| upcoming flu season | 0.477548 |
| antigenic drift | 0.307304 |
| research program | 0.246112 |
| yearly flu vaccine | 0.573896 |
| previous flu vaccinations | 0.495563 |
| time-consuming production process | 0.293358 |
| vaccine platforms | 0.325389 |
| vaccine effectiveness | 0.327853 |
| pandemic influenza research | 0.321638 |
| multiple flu strains | 0.573276 |
| human flu viruses | 0.500005 |
| influenza surveillance | 0.277497 |
| seasonal flu viruses | 0.515262 |
| Scientists | 0.218194 |
|
| influenza vaccine production | 0.39304 |
| universal flu vaccine | 0.691041 |
| multiple flu subtypes | 0.458878 |
| multiple flu seasons | 0.518895 |
| basic understanding | 0.248089 |
| Influenza pandemics | 0.282272 |
| U.S. Centers | 0.25193 |
| changes | 0.229679 |
| flu vaccine | 0.97962 |
| dominant strains | 0.296906 |
| globally circulating flu | 0.490336 |
| potential pandemic strains | 0.361387 |
| immune response | 0.256994 |
| person-to-person | 0.211008 |
| flu vaccine research | 0.531986 |
| seasonal flu vaccine | 0.95459 |
| protections | 0.210719 |
| vaccine strains | 0.377045 |
| NIAID | 0.29333 |
| unexpected flu strain | 0.481882 |
| people | 0.229954 |
| flu vaccine strain | 0.555725 |
| poor match | 0.24891 |
| key focus | 0.246436 |
|
CLICK HERE |
| 15538 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
NIAID's Programs on Asthma in the Inner City |
Recognizing that asthma severity in inner-city children is disproportionately high, NIAID has sponsored research to reduce the public health burden that asthma presents in inner-city populations. Beginning in 1991, NIAID has supported three consecutive inner-city asthma research programs, which have been successful in reducing asthma severity in children. |
| inner-city populations | 0.579525 |
| Morgan WJ | 0.496915 |
| cockroach allergen | 0.471241 |
| inner-city children. | 0.516784 |
| asthma severity | 0.746089 |
| inner-city adolescents | 0.569622 |
| environmental intervention study | 0.506189 |
| clinical trials | 0.457073 |
| Infectious Diseases networks | 0.482159 |
| asthma exacerbations | 0.604543 |
| asthma attacks | 0.618501 |
| Gergen PJ | 0.506952 |
| City Anti-IgE Therapy | 0.499916 |
| asthma | 0.9777 |
| Pongracic JA | 0.498 |
| Szefler SJ | 0.504609 |
| Busse WW. Management | 0.518055 |
| Asthma Control Evaluation | 0.678562 |
| asthma treatment guidelines | 0.681693 |
| Gruchalla RS | 0.496061 |
| Allergy Clin Immunol. | 0.483813 |
| Busse WW. | 0.518705 |
| asthma management | 0.634222 |
| omalizumab | 0.464849 |
| severe allergic asthma | 0.661933 |
|
| asthma morbidity | 0.639521 |
| ICAC investigators | 0.510592 |
| CA. Randomized trial | 0.488723 |
| guidelines-based asthma therapy | 0.667931 |
| asthma presents | 0.660928 |
| nitric oxide level | 0.504737 |
| William Busse | 0.501488 |
| follow-on clinical trial | 0.490114 |
| asthma treatment | 0.724256 |
| public health burden | 0.502806 |
| exhaled nitric oxide | 0.589522 |
| at-risk children | 0.467554 |
| inner city | 0.546793 |
| Liu AH | 0.496615 |
| Teach SJ | 0.501285 |
| clinical guidelines | 0.486081 |
| principal investigators | 0.485986 |
| Asthma counselors | 0.64051 |
| ICAC program | 0.497263 |
| inner-city asthma research | 0.793594 |
| basic research sites | 0.543997 |
| year-long study | 0.459719 |
| inner-city children | 0.771731 |
| asthma symptoms | 0.641572 |
|
CLICK HERE |
| 15540 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
NIAID Paylines -- NIAID Research Funding |
Fiscal year paylines for all award types. |
| Final NIAID Paylines | 0.905895 |
| POs contact information | 0.229921 |
| interim paylines | 0.666704 |
| success rates | 0.214968 |
| Email Alerts | 0.25735 |
| NIAID funds | 0.432012 |
|
| Research Project Success | 0.236611 |
| program officer | 0.217587 |
| overall impact/priority score | 0.255863 |
| initial paylines | 0.594349 |
| Research Portfolio Online | 0.237047 |
|
CLICK HERE |
| 15548 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Tuberculosis TB, NIAID, NIH |
NIAID is examining TB at its fundamental levels through research to develop faster diagnosis, better vaccines, and shorter treatment times. |
| animal models | 0.484339 |
| treatment strategies | 0.479645 |
| new TB drug | 0.750789 |
| drug-resistant strains | 0.584127 |
| multidrug-resistant TB | 0.705257 |
| optimal drug combinations | 0.547291 |
| TB disease | 0.789313 |
| research findings | 0.480296 |
| severe airborne disease | 0.575915 |
| research | 0.505253 |
| new candidate drugs | 0.571748 |
| death worldwide | 0.485014 |
| novel TB drugs | 0.766874 |
| national history | 0.484991 |
| candidate drugs | 0.572469 |
| active TB disease | 0.746928 |
| TB deaths | 0.714042 |
| major causes | 0.487119 |
| MedlinePlus tuberculosis site | 0.583865 |
| genetic drug | 0.486206 |
| comprehensive portfolio | 0.485226 |
| TB bacterium | 0.688383 |
| latent infections | 0.478461 |
| middle-income countries | 0.49248 |
|
| risk factors | 0.478783 |
| World Health Organization | 0.559465 |
| research infrastructure | 0.479568 |
| early TB disease | 0.745692 |
| NIAID | 0.606471 |
| diagnostic potential | 0.480354 |
| people | 0.530993 |
| TB | 0.982786 |
| biomedical research | 0.486422 |
| new TB drugs | 0.754513 |
| HIV deaths | 0.484548 |
| Mycobacterium tuberculosis | 0.614224 |
| private industry | 0.478347 |
| public health practices | 0.540649 |
| TB diagnosis | 0.691172 |
| clinical studies | 0.55766 |
| prevention strategies | 0.478336 |
| NIAID priority | 0.54559 |
| vaccine clinical trials | 0.538763 |
| Mtb | 0.530457 |
| drug resistance | 0.554266 |
| causative agent | 0.484545 |
| basic research | 0.485797 |
|
CLICK HERE |
| 15550 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Intramural NIAID Research Opportunities INRO, NIH |
INRO is an NIAID 4-day exploratory program that connects minority science students with training opportunities in immunology and infectious diseases. |
| INRO email updates | 0.738453 |
| financially disadvantaged backgrounds | 0.982393 |
| multi-disciplinary research facility | 0.838981 |
| recent hurricanes | 0.496559 |
| medical students | 0.522578 |
| research training experience | 0.829391 |
| program | 0.227182 |
|
| NIAID | 0.411192 |
| biomedical research | 0.532386 |
| hardship | 0.209827 |
| hotel accommodations | 0.500268 |
| application process | 0.466663 |
| difficult time | 0.488892 |
| diverse research community | 0.837556 |
|
CLICK HERE |
| 15554 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Biodefense Category A, B, C Pathogens |
NIAID biodefense Category A, B, C pathogens |
| Additional Emerging Infectious | 0.832106 |
| Centers | 0.421008 |
| host defenses | 0.530437 |
| United States | 0.52892 |
| NIAIDÂ biodefense/EID mission | 0.732951 |
| highest priority | 0.718109 |
| Category C pathogens | 0.679223 |
| Biodefense Research | 0.623199 |
| U.S. Department | 0.53081 |
| complete scope | 0.522633 |
| Prevention | 0.420958 |
| conjunction | 0.425199 |
| Disease Control | 0.527974 |
| geographic range | 0.544192 |
| Emerging Infectious Diseases/Pathogens | 0.964432 |
| priority pathogens | 0.731074 |
| public health | 0.526578 |
| Notes | 0.420393 |
| pathogen threats | 0.55739 |
|
| national security | 0.524884 |
| HIV/AIDS | 0.422564 |
| Diseases/Pathogens category | 0.607089 |
| federal partners | 0.531115 |
| NIAID Emerging Infectious | 0.962085 |
| priority organisms/biological agents | 0.689595 |
| Category B pathogens | 0.686236 |
| Homeland Security | 0.535344 |
| intramural program management | 0.634748 |
| revision | 0.425668 |
| population | 0.422041 |
| NIAID Category | 0.742626 |
| biodefense effort | 0.588256 |
| highest risk | 0.556143 |
| pathogen priority list | 0.734849 |
| mass dissemination | 0.523841 |
| threat assessments | 0.532316 |
| Immunology studies | 0.522128 |
|
CLICK HERE |
| 15980 |
National Institute of Allergy and Infectious Diseases |
Video |
en |
Understanding Food Allergy |
The National Institute of Allergy and Infectious Diseases explains food allergy and offers tips on how to manage the condition. |
| TEDx Talks | 0.301209 |
| Food Allergy Enigma | 0.427335 |
| WARNING Signs | 0.307007 |
| Allergy Skin Tests | 0.422724 |
| ABS-CBN News | 0.319963 |
| Food Allergies | 0.800849 |
| Steve Paikin | 0.306473 |
| tips | 0.220462 |
| Untreated allergic reactions | 0.428934 |
| Mo10ta | 0.219842 |
| Anaphylaxis-Mayo Clinic | 0.294736 |
| Severe Food Allergies | 0.523532 |
| Sonia Hunt | 0.304266 |
| Duration | 0.977395 |
| Good Morning | 0.305532 |
| Dr. John Bergman | 0.374323 |
| eMedTV | 0.221562 |
| Stay Safe | 0.301006 |
| symptoms | 0.217567 |
| condition | 0.220423 |
| Infectious Diseases | 0.318448 |
| Foods | 0.218524 |
| Food Allergens | 0.31897 |
| Live Healthy | 0.301596 |
| Gluten Intolerance | 0.31617 |
|
| Mayo Clinic | 0.294446 |
| Cure Allergies FAST | 0.483591 |
| Signature Medical Group | 0.391029 |
| Food Intolerances | 0.341701 |
| boy | 0.235485 |
| Allergies Are Tired | 0.41865 |
| ABC News | 0.406616 |
| America | 0.2185 |
| Food Can Kill | 0.320007 |
| Severe Food Allergy | 0.452133 |
| views | 0.647848 |
| National Institute | 0.318188 |
| Immune Response | 0.297675 |
| Sensitivities | 0.221006 |
| Agenda | 0.21749 |
| NIAID | 0.224612 |
| food allergy | 0.513642 |
| Food Control Plan | 0.393618 |
| TEDxUCDavisSF | 0.217779 |
| Fatal Allergies | 0.417301 |
| National Geographic | 0.373164 |
| Rita Mustafa | 0.302426 |
| PsycheTruth | 0.219651 |
| Ana Pena | 0.303769 |
|
CLICK HERE |